Therapeutic Outcome of Fluorescence Cystoscopy Guided Transurethral Resection in Patients with Non-Muscle Invasive Bladder Cancer: A Meta-Analysis of Randomized Controlled Trials

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yuan, Haichao ^a   Qiu, Jianguo ^a   Liu, Liangren ^a   Zheng, Shuo ^a   Yang, Lu ^a   Liu, Zhenghua ^a   Pu, Chunxiao ^a   Li, Jinhong ^a   Wei, Qiang ^a   Han, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; HEXYLAMINOLEVULINIC ACID; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CYSTOSCOPY; ENDOSCOPIC SURGERY; FLUORESCENCE CYSTOSCOPY; FLUORESCENCE CYSTOSCOPY GUIDED TRANSURETHRAL RESECTION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK REDUCTION; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; WHITE LIGHT CYSTOSCOPY;

AGED; CARCINOMA IN SITU; CYSTOSCOPY; DATABASES, BIBLIOGRAPHIC; DISEASE PROGRESSION; FEMALE; FLUORESCENCE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURGERY, COMPUTER-ASSISTED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84884151142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074142     Document Type: Article

References (35)

1. Daniltchenko D, Riedl CR, Sachs MD, Koenig F, Daha KL, et al. (2005) Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174: 2129-2133. doi:10.1097/01.ju.0000181814.73466.14.
2. Al, '-Shukri SKh, Danil'chenko DI, Kënig F, Shnorr D, (2000) ALA fluorescent diagnosis of bladder cancer. Urologiia 5: 48-50.
3. Sylvester RJ, vander Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-475. doi:10.1016/j.eururo.2005.12.031.
4. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, et al. (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174: 862-866. doi:10.1097/01.ju.0000169257.19841.2a.
5. Witjes JA, (2004) Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45: 142-146. doi:10.1016/j.eururo.2003.09.013.
6. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, et al. (1994) Fluorescence photodetection of neoplastic urothelial lesions follow-ing intravesical instillation of 5-aminolevulinic acid. Urology 44: 836-841. doi:10.1016/S0090-4295(94)80167-3.
7. Kausch I, Sommerauer M, Montorsi FS, Stenzl A, Jacqmin D, et al. (2010) Photodynamic Diagnosis in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies. Eur Urol 57: 595-606. doi:10.1016/j.eururo.2009.11.041.
8. Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA, (2012) Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol 30: 285-289. doi:10.1016/j.urolonc.2010.09.009.
9. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, et al. (2011) EAU guidelines on non-muscle-inva-sive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997-1008. doi:10.1016/j.eururo.2011.03.017.
10. Mowatt G, N'Dow J, Vale L, Nabi G, Boachie C, et al. (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care 27: 3-10. doi:10.1017/S0266462310001364.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. doi:10.1016/S0197-2456(96)90740-0.
12. Higgins JPT, Green S, (2009) Cochrane handbook for systematic reviews of interventions, version 5.0.2 updated September 2009. The Cochrane Collaboration. Available: http://cochrane.org/resources/handbook/.
13. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, et al. (2001) Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165: 1121-1123. doi:10.1016/S0022-5347(05)66442-7.
14. Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, et al. (2002) Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168: 475-478. doi:10.1016/S0022-5347(05)64661-7.
15. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W, (2002) clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 168: 67-71. doi:10.1016/S0022-5347(05)64833-1.
16. Babjuk M, Soukup V, Petrík R, Jirsa M, Dvorácek J, (2005) 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 96: 798-802. doi:10.1111/j.1464-410X.2004.05715.x. PubMed: 16153204.
17. Schumacher MC, Holmäng S, Davidsson T, Friedrich B, Pedersen J, et al. (2010) Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57: 293-299. doi:10.1016/j.eururo.2009.10.030.
18. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, et al. (2011) Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: A multicenter randomized, double-blind, placebo-controlled trial. Cancer 117: 938-947. doi:10.1002/cncr.25523.
19. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, et al. (2010) Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 184: 1907-1913. doi:10.1016/j.juro.2010.06.148.
20. Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, et al. (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188: 58-62. doi:10.1016/j.juro.2012.03.007.
21. Drǎgoescu O, Tomescu P, Pǎnuş A, Enache M, Maria C, et al. (2011) Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol 52: 123-127.
22. Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, et al. (2012) Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int 109: 549-556. doi:10.1111/j.1464-410X.2011.10374.x.
23. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S, (2011) Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 108: E297-E303. doi:10.1111/j.1464-410X.2011.10090.x.
24. Karaolides T, Skolarikos A, Bourdoumis A, Konandreas A, Mygdalis V, et al. (2012) Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 80: 354-359. doi:10.1016/j.urology.2012.03.067.
25. Shen P, Yang J, Wei W, Li Y, Li D, et al. (2012) Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int 110: E209-E215. doi:10.1111/j.1464-410X.2011.10892.x.
26. Isfoss BL, (2011) The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int 108: 1703-1707. doi:10.1111/j.1464-410X.2011.10485.x.
27. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, et al. (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging:a prospective, phase III multicenter study. J Urol 174: 862-866. doi:10.1097/01.ju.0000169257.19841.2a.
28. Botteman MF, Pashos CL, Redaelli A, Zeylemaker B, van Moorselaar J, et al. (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330. doi:10.1007/BF03262330.
29. Burger M, Zaak D, Stief CG, Filbeck T, Wieland WF, et al. (2007) Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany based cost analysis. Eur Urol 52: 142-147. doi:10.1016/j.eururo.2007.01.064.
30. Malmström PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, et al. (2009) Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 43: 192-198. doi:10.1080/00365590902808541. PubMed: 19330681.
31. Herr HW, (1990) Outpatient flexible cystoscopy and fulguration of recurrent superficial bladder tumors. J Urol 144: 1365-1366.
32. Grossman HB, Gomella LG, Fradet Y, Presti JC Jr, Ritenour CWM, et al. (2004) The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder. J Urol 171: 69.
33. Loidl W, Schmidbauer J, Susani M, Marberger M, (2005) Flexible cystoscopy assisted by hexaminolevulinate induced fluores-cence: a new approach for bladder cancer detection and surveillance? Eur Urol 47: 323-326. doi:10.1016/j.eururo.2004.10.025. PubMed: 15716195.
34. Witjes JA, Moonen PM, van der Heijden AG, (2005) Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder can-cer: results of a prospective Phase II study. Eur Urol 47: 319-322. doi:10.1016/j.eururo.2004.09.017. PubMed: 15716194.
35. Hermann GG, Mogensen K, Toft BG, Glenthøj A, Pedersen HM, (2012) Outpatient diagnostic of bladder tumours in flexible cystoscopes: evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol 46: 31-36. doi:10.3109/00365599.2011.637954.